These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 27644904)

  • 41. Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: A nationwide study.
    van der Werf LR; Dikken JL; van der Willik EM; van Berge Henegouwen MI; Nieuwenhuijzen GAP; Wijnhoven BPL;
    Eur J Cancer; 2018 Mar; 91():76-85. PubMed ID: 29353163
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Response to definitive chemoradiotherapy and survival in patients with an oesophageal adenocarcinoma versus squamous cell carcinoma: a matched-pair analysis.
    Tougeron D; Di Fiore F; Hamidou H; Rigal O; Paillot B; Michel P
    Oncology; 2007; 73(5-6):328-34. PubMed ID: 18497505
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Isolated local recurrence or solitary solid organ metastasis after esophagectomy for cancer is not the end of the road.
    Depypere L; Lerut T; Moons J; Coosemans W; Decker G; Van Veer H; De Leyn P; Nafteux P
    Dis Esophagus; 2017 Jan; 30(1):1-8. PubMed ID: 27704661
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Can definitive chemoradiotherapy be an alternative to surgery for early-stage oesophageal cancer?
    Deng HY; Li G; Luo J; Alai G
    Interact Cardiovasc Thorac Surg; 2019 Jan; 28(1):37-40. PubMed ID: 30007292
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chemoradiation in oesophageal cancer.
    Dai T; Shah MA
    Best Pract Res Clin Gastroenterol; 2015 Feb; 29(1):193-209. PubMed ID: 25743466
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
    Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Surgical approach and results of surgery in adenocarcinoma of the gastro-oesophageal junction.
    Ti TK
    Singapore Med J; 2000 Jan; 41(1):14-8. PubMed ID: 10783674
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase I/II study of oxaliplatin and paclitaxel in patients with non-resectable cancer of the oesophagus and adenocarcinoma of the gastro-oesophageal junction: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Kaechele V; Moehler M; Lutz MP; von Wichert G; Eisele M; Klaus J; Galle PR; Adler G; Seufferlein T
    Cancer Chemother Pharmacol; 2010 May; 66(1):191-5. PubMed ID: 20354701
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic value of metabolic response measured by 18F-FDG-PET in oesophageal cancer patients treated with definitive chemoradiotherapy.
    Onal C; Torun N; Guler OC; Yildirim BA
    Nucl Med Commun; 2016 Dec; 37(12):1282-1289. PubMed ID: 27612030
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Definitive chemoradiotherapy in patients with esophageal adenocarcinoma: an alternative to surgery?
    Tougeron D; Scotté M; Hamidou H; Di Fiore F; Paillot B; Michot F; Michel P
    J Surg Oncol; 2012 Jun; 105(8):761-6. PubMed ID: 22124932
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction.
    Ku GY; Ilson DH
    Expert Rev Anticancer Ther; 2008 Dec; 8(12):1953-64. PubMed ID: 19046115
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer.
    Bascoul-Mollevi C; Gourgou S; Galais MP; Raoul JL; Bouché O; Douillard JY; Adenis A; Etienne PL; Juzyna B; Bedenne L; Conroy T
    Eur J Cancer; 2017 Oct; 84():239-249. PubMed ID: 28829992
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of chemoradiotherapy in oesophageal cancer -- adjuvant and neoadjuvant therapy.
    Gwynne S; Wijnhoven BP; Hulshof M; Bateman A
    Clin Oncol (R Coll Radiol); 2014 Sep; 26(9):522-32. PubMed ID: 24947234
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
    Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
    Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Overview of multimodal therapy for adenocarcinoma of the esophagogastric junction.
    Hosoda K; Yamashita K; Katada N; Watanabe M
    Gen Thorac Cardiovasc Surg; 2015 Oct; 63(10):549-56. PubMed ID: 26232357
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Lymph node involvement in œsophageal cancer: surgical approach].
    Gronnier C; Mariette C
    Cancer Radiother; 2014 Oct; 18(5-6):559-64. PubMed ID: 25195112
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Systematic review and meta-analysis on the significance of salvage esophagectomy for persistent or recurrent esophageal squamous cell carcinoma after definitive chemoradiotherapy.
    Kumagai K; Mariosa D; Tsai JA; Nilsson M; Ye W; Lundell L; Rouvelas I
    Dis Esophagus; 2016 Oct; 29(7):734-739. PubMed ID: 26316181
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Symptoms, investigations and management of patients with cancer of the oesophagus and gastro-oesophageal junction in Australia.
    Smithers BM; Fahey PP; Corish T; Gotley DC; Falk GL; Smith GS; Kiroff GK; Clouston AD; Watson DI; Whiteman DC
    Med J Aust; 2010 Nov; 193(10):572-7. PubMed ID: 21077812
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Incidence and pathologic distribution of esophageal cancers at the gastro-esophageal junction between 1993-2003].
    Lakatos PL; Lakatos L; Fuszek P; Lukovich P; Kupcsulik P; Halbász J; Schaff Z; Papp J
    Orv Hetil; 2005 Feb; 146(9):411-6. PubMed ID: 15830608
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer.
    Cartwright E; Cunningham D
    Curr Treat Options Oncol; 2017 Nov; 18(12):69. PubMed ID: 29143893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.